| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/10/2003 | WO2002074238A3 Water soluble and palatable complexes |
| 04/10/2003 | WO2002072826A3 Neurotrophic factors |
| 04/10/2003 | WO2002071827A3 Retinoid x receptor modulators |
| 04/10/2003 | WO2002070551A3 Neuritogenic compound and uses thereof |
| 04/10/2003 | WO2002070070A3 Compositions having improved bioavailability of eletriptan |
| 04/10/2003 | WO2002062383A3 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
| 04/10/2003 | WO2002060423A3 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/10/2003 | WO2002059083A3 Novel compounds |
| 04/10/2003 | WO2002057460A3 Polynucleotides encoding human phosphatases |
| 04/10/2003 | WO2002053169A8 Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration |
| 04/10/2003 | WO2002053104A3 Use of catecholamine reuptake inhibitors to enhance memory |
| 04/10/2003 | WO2002049629A3 Methods for reducing chronic stress in mammals |
| 04/10/2003 | WO2002041889A3 Indolsulfonyl compounds useful in the treatment of cns disorders |
| 04/10/2003 | WO2002040666A3 Fat regulated genes, uses thereof, and compounds for modulating same |
| 04/10/2003 | WO2002028889A3 Haemophilus influenzae antigens and corresponding dna fragments |
| 04/10/2003 | WO2002017896A3 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | US20030069445 Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide |
| 04/10/2003 | US20030069430 Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects |
| 04/10/2003 | US20030069429 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 04/10/2003 | US20030069416 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives |
| 04/10/2003 | US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders |
| 04/10/2003 | US20030069393 Compound for use in the treatment of cancer and prevention of infections |
| 04/10/2003 | US20030069316 Use of comt inhibitors as analgesics |
| 04/10/2003 | US20030069313 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 04/10/2003 | US20030069306 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/10/2003 | US20030069304 Antidepressants |
| 04/10/2003 | US20030069296 Central nervous system disorders |
| 04/10/2003 | US20030069294 Alpha-substituted carboxylic acid derivatives |
| 04/10/2003 | US20030069292 Central nervous system disorders; anticonvulsants |
| 04/10/2003 | US20030069290 Substituted-heteroaryl-7-aza[2.2.1] bycycloheptanes for the treatment of desease |
| 04/10/2003 | US20030069289 Alzheimer*s disease |
| 04/10/2003 | US20030069288 Substituted aminomethyl-phenyl-cyclohexane derivatives |
| 04/10/2003 | US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 04/10/2003 | US20030069278 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 04/10/2003 | US20030069274 Pharmaceutically active compounds and methods of use |
| 04/10/2003 | US20030069263 Prevention drug abruse; analgesics |
| 04/10/2003 | US20030069262 Neutral antagonists and use thereof in treating drug abuse |
| 04/10/2003 | US20030069260 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 04/10/2003 | US20030069257 Benzimidazole and pyridylimidazole derivatives |
| 04/10/2003 | US20030069254 New arylsulfonyl derivatives with 5-HT6 receptor affinity |
| 04/10/2003 | US20030069249 Analgesics; central nervous system disorders |
| 04/10/2003 | US20030069246 Central nervous system disorders; psychological disorders; cardiovascular disorders |
| 04/10/2003 | US20030069243 Novel substituted imidazole compounds |
| 04/10/2003 | US20030069241 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents |
| 04/10/2003 | US20030069238 Anticancer agents; immunology diseases; antiallergens; antiinflammatory agents |
| 04/10/2003 | US20030069233 Central nervous system disorders; psychological disorders; Alzheimer's disease |
| 04/10/2003 | US20030069228 Capase inhibitors; antiinflammatory agents |
| 04/10/2003 | US20030069217 Methods of prevention and treatment of ischemic damage |
| 04/10/2003 | US20030069216 Interconversion of inactive 11- keto steroids with their active 11B-hydroxy equivalents, especially between cortisone and cortisol; administering a 11-beta-reductase inhibitor such as carbenoxolone |
| 04/10/2003 | US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives |
| 04/10/2003 | US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 04/10/2003 | US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 04/10/2003 | US20030069190 Alkali and alkaline earth metal salts of topiramate |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| 04/10/2003 | US20030069166 Uses an anisaldehyde as the stimulative agent. |
| 04/10/2003 | US20030068664 Monitoring effectiveness of preferential cancer immunotherapy; obtain mammal, administer immunotherapy, evaluate effectiveness of treatment |
| 04/10/2003 | US20030068330 Nerve growth factor activity potentiating agents |
| 04/10/2003 | US20030068325 A peptide immunogen of about 20 to 100 amino acids long comprising: a helper T cell (Th) epitope, an N-terminal fragment of A beta 1-42 peptide, consisting from 10-28 amino acid residues |
| 04/10/2003 | US20030068276 Dosage forms |
| 04/10/2003 | CA2462851A1 Hydroxypropylamines |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462682A1 The use of gammaglobulin for the treatment of immune-mediated diseases |
| 04/10/2003 | CA2462661A1 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| 04/10/2003 | CA2462643A1 Triazepine derivatives as neurotrophic agents |
| 04/10/2003 | CA2462419A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 04/10/2003 | CA2462142A1 Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system |
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2462110E Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 04/10/2003 | CA2462030A1 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 04/10/2003 | CA2461895A1 Use of mannosamine derivatives for the stimulation of neurite growth |
| 04/10/2003 | CA2461723A1 A method of simultaneously treating sensory auditory gating deficit and associated psychosis in schizophrenia and bipolar disorder patients with mania |
| 04/10/2003 | CA2461670A1 Indole derivatives as cox ii inhibitors |
| 04/10/2003 | CA2461381A1 Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| 04/10/2003 | CA2461304A1 Screening process for various indications using bnpi and/or dnpi |
| 04/10/2003 | CA2461292A1 Apo-2 ligand variants and uses thereof |
| 04/10/2003 | CA2461213A1 Process for the preparation of citalopram |
| 04/10/2003 | CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| 04/10/2003 | CA2461034A1 Tetrahydroisochinolines, their production and the use thereof as analgesics |
| 04/10/2003 | CA2460594A1 Mch receptor antagonists |
| 04/10/2003 | CA2460168A1 4¬piperidin-4-yliden-(3-carbamoylphenyl)methyl| benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders |
| 04/10/2003 | CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | CA2457647A1 Benzimidazolidinone derivatives as muscarinic agents |
| 04/10/2003 | CA2455389A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/10/2003 | CA2453343A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 04/10/2003 | CA2430328A1 Receptor antagonist |
| 04/09/2003 | EP1300467A1 Novel polypeptide and dna thereof |
| 04/09/2003 | EP1300416A1 Memory-enhancing peptides and the use thereof |
| 04/09/2003 | EP1300396A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| 04/09/2003 | EP1300395A1 4-substituted piperidine compound |
| 04/09/2003 | EP1300155A1 Enteric preparations containing physiologically active peptides |
| 04/09/2003 | EP1300148A2 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 04/09/2003 | EP1300145A1 Therapeutic or preventive medicines for mood disorders or anxiety disorders |
| 04/09/2003 | EP1300144A2 Paroxetine in treatment of depression |
| 04/09/2003 | EP1300140A1 Long release matricial formulations of pirlindol hydrochloride |
| 04/09/2003 | EP1299548A1 Novel therapeutic molecular variants and uses thereof |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299542A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |